210 related articles for article (PubMed ID: 21915635)
1. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
[TBL] [Abstract][Full Text] [Related]
2. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Ait-Tihyaty M; Rachid Z; Larroque-Lombard AL; Jean-Claude BJ
Invest New Drugs; 2013 Dec; 31(6):1409-23. PubMed ID: 23959266
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
4. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
[TBL] [Abstract][Full Text] [Related]
5. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
6. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
7. Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
Wan L; Cao D; Zeng J; Yan R; Pizzorno G
Mol Pharmacol; 2006 Apr; 69(4):1389-95. PubMed ID: 16397116
[TBL] [Abstract][Full Text] [Related]
8. [Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP].
Li G; Yan CY; Wen DG; Ding Q; Zhang YF
Ai Zheng; 2004 Aug; 23(8):929-32. PubMed ID: 15301717
[TBL] [Abstract][Full Text] [Related]
9. Rational design of new tumoractivated cytotoxic agents.
Verweij J
Oncology; 1999 Jul; 57 Suppl 1():9-15. PubMed ID: 10436411
[TBL] [Abstract][Full Text] [Related]
10. [Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
Ye D; Wang Q; Zhang J; Liu Q
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):18-24. PubMed ID: 25877313
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.
Damaraju VL; Mowles D; Wilson M; Kuzma M; Cass CE; Sawyer MB
Biochem Cell Biol; 2013 Dec; 91(6):419-27. PubMed ID: 24219283
[TBL] [Abstract][Full Text] [Related]
12. Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
Fischel JL; Ferrero JM; Formento P; Ciccolini J; Renée N; Formento JL; Milano G
Anticancer Drugs; 2005 Mar; 16(3):309-16. PubMed ID: 15711183
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
15. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Evrard A; Cuq P; Ciccolini J; Vian L; Cano JP
Br J Cancer; 1999 Aug; 80(11):1726-33. PubMed ID: 10468288
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
[TBL] [Abstract][Full Text] [Related]
17. Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Zhu Y; Xu L; Fan Y; Li C; Zhang Y; Zheng H; Hou K; Qu X; Liu Y
Biomed Res Int; 2013; 2013():132793. PubMed ID: 24027750
[TBL] [Abstract][Full Text] [Related]
18. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
19. Induction of thymidine phosphorylase expression by AZT contributes to enhancement of 5'-DFUR cytotoxicity.
Tsuneyoshi K; Haraguchi M; Hongye Z; Gotanda T; Tachiwada T; Sumizawa T; Furukawa T; Baba M; Akiyama S; Nakagawa M
Cancer Lett; 2006 Dec; 244(2):239-46. PubMed ID: 16457948
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
